Redeye makes some downward adjustments to our near-term forecasts as order bookings have been slow lately.
Sales and earnings in the fourth quarter are mainly in line with our estimates.
Redeye comments on Freemelt ahead of Q4 and full year results.
Redeye remains confident on the case as we see solid prospects for continued rapid growth and good operating leverage.
Redeye comments on Freemelt’s Q3 report, which was slightly better than we expected.
Redeye expects another quarter with high activity in terms of deliveries and reported sales.
Redeye updates its estimates following Freemelt’s Q2 report, which was a record quarter, both in terms of revenues and order intake.
Six Freemelt ONE orders and sales of SEK 19m mark record quarter Estimates intact, deviation from ABGSCe only due to delivery timings eMELT ...
Redeye comments on Freemelt’s Q2 results, which marked a record quarter for the company, with revenues almost surpassing those for the full ...
Q2 sales on par with FY'24, below ABGSCe only on delivery timings Deliveries likely pushed into H2, so limited impact on cons.
Redeye comments on Freemelt ahead of its Q2 results.
- Expect strong sales of SEK 29m supported by intra-quarter deliveries - Order influx encouraging, but volatility prevents us from extrapola...
Redeye provides a brief comment on today’s news that Freemelt has signed an agreement with a leading Chinese industrial player to enter seve...
Redeye updates its estimates following Freemelt’s Q1 report, which came in lower than expected in terms of sales, while cost control was bet...
Soft Q1 sales of SEK 2.9m on no machine deliveries, but 6 orders Share issue readies balance sheet for year of commercialisation 6 deliverie...
Redeye interviewed Freemelt’s CEO, Daniel Gidlund, about the Q1 report and recently announced orders.
Redeye comments on Freemelt’s Q1 results, which were softer than expected in terms of sales, while costs came in below our estimates.
Sales SEK 2.9m, EBIT adj. -12m vs. cons. 7.7m and -9.
Redeye updates its estimates following Freemelt’s Q4 report, which came in above our expectations in terms of sales.
Q4 sales pre-announced, SEK -10.7m adj. EBIT in line with ABGSCe Rights issue concluded, 1 Freemelt ONE, 1 eMELT-iD order in Q1 28 paid deve...
Redeye comments on Freemelt’s Q4 results, which were in line with the preliminary figures the company published in conjunction with the righ...
Redeye provides a comment on Freemelt’s new order from Saab.
Redeye comments on the outcome of Freemelt’s rights issue.
Redeye provides a brief comment on the final rights issue terms announced yesterday.
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes on lower SP Full Q4 report on 28 March, ...
Redeye comments on Freemelt’s preliminary Q4 figures, which came in stronger than expected in terms of sales.
Announces some preliminary Q4 figures due to rights issue Sales SEK 8.
Q4 report postponed to 28 March due to rights issue Preliminary Q4 figures to be published around 27 January At current SP, we estimate 83m ...
Redeye comments on Freemelt ahead of its Q4 results.
Redeye comments on Freemelt’s plan to resolve a SEK100m rights issue, with 90% secured through subscription commitments and guarantee undert...
Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in above our expectations.
Deliveries and sales in line, somewhat lower costs than expected Update on development studies and stages, interest seems strong eMELT-iD sa...
Sales -2%, adj. EBIT +4m vs. FactSet consensus Better EBIT largely driven by improved cost control Expects to see increased volumes, with mu...
Redeye comments on Freemelt’s Q3 results, which were roughly in line with expectations in terms of sales, while margins were better than ant...
Q3e: Two Freemelt ONE deliveries, sales SEK 9.3m, EBIT -24m Estimates down on slower-than-expected eMELT orders Remain confident in future s...
Redeye provides a brief comment on Freemelt's order from a global orthopedic implant OEM, marking a significant step toward becoming a trust...
Redeye comments on Freemelt ahead of its Q3 results, due on 5 November.
Q2 sales low due to delivery delay, SEK 12m already secure for H2 Elevated opex due to new and replaced personnel, as well as eMELT Sales la...
Redeye updates its estimates and valuation following Freemelt’s Q2 report, which came in below our expectations due to the timing effect of ...
Redeye comments on Freemelt’s Q2 results, which came in lower than expected because some anticipated printer orders were not delivered durin...
Sales SEK 2.4m vs. cons. 13m due to incomplete eMELT-iD delivery EBIT adj.
Q2e: one eMELT-iD and two Freemelt ONE deliveries Sales of SEK 13.
Redeye comments on Freemelt ahead of its Q2 results, due on 6 August.
Redeye provides a brief comment on the new partnership with Mid Sweden University and Sandvik.
Redeye updates its estimates and valuation following Freemelt’s Q1 report, which fell below expectations due to no printer deliveries in the...
Q1: sales SEK 0.82m, adj. EBIT -12m, no deliveries Q2 to be more eventful, SEK 12m of orders announced First eMELT in Q2, Saab and UKAEA pro...
Redeye comments on Freemelt’s Q1 results, which came in lower than expected in terms of sales due to no printer delivery in the quarter.
No deliveries in Q1 compared to one Freemelt ONE expected Opex being kept under control despite investments First eMELT order received in Q2...
Q1e: one Freemelt ONE delivery, SEK 4.9m sales, SEK -8.
Redeye has interviewed Freemelt’s regional presidents of the Americas and EMEA.
Redeye comments on Freemelt’s new order from UKAEA, which deepens Freemelt’s position within the fusion energy sector.
Redeye comments on Freemelt’s first industrial printer (eMelt) order in the US and provides a preview ahead of the company’s Q1 results (due...
Redeye comments on Freemelt’s new order from Saab Dynamics.
Redeye comments on today’s news where Freemelt announced its intention to carry out a fully secured rights issue of SEK66m.
Sales SEK 7.6m (12.2m), adj. EBIT SEK -18.0m (-8.6m) Several strategic agreements signed, investing and marketing Roll-out of eMELT-iD in '2...
Redeye updates its estimates and valuation following Freemelt’s Q4 report, which exceeded expectations due to an additional printer delivery...
Redeye comments on Freemelt’s Q4 results, which were significantly better than expected in terms of sales.
Sales +110%, adj. EBIT SEK -0.5m vs. ABGSCe Some more revenue recognised in this quarter, order book SEK 1.
Redeye comments on Freemelt’s agreement with WEAREAM, which marks an important step in the ongoing commercialization phase of the industrial...
Redeye comments on Freemelt ahead of its Q4 results (due 20 Feb).
Q4e: Two deliveries, sales only SEK 3.6m due to payment model '24e the year of e-MELT ID, '25e the year of e-MELT IM Expect a more careful r...
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in somewhat weaker than expected in terms of sales.
Sales SEK 8.2m, up 2% y-o-y: one delivery, two orders First eMELT delivery in '24e now highly likely Management comment provides potential u...
Sales -20.6%, adj. EBIT -2.6% vs. ABGSCe, improved cost control Expects increasing demand for eMELT in '24, volume orders in '25 Strategic c...
Redeye comments on Freemelt’s Q3 results, which were somewhat softer than expected in terms of sales, while profitability came in above expe...
Q3e: Two Freemelt ONE deliveries, sales SEK 10.3m, up 28% y-o-y First eMELT agreement with large global production company No significant es...
Redeye comments on Freemelt ahead of its Q3 results (due 8 Nov).
Redeye comments on Freemelt’s agreement for the industrial printer (eMELT) with a leading global technology company, marking a significant m...
Strides in tungsten and titanium processing Commercialised sales organisation will drive order flow Anticipate initial e-MELT delivery in Q1...
